Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors.
BRD4
BRD4-NUT
Checkpoint inhibitor
NUT carcinoma
NUT midline carcinoma
PD-L1
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
16
11
2020
revised:
20
07
2021
accepted:
20
07
2021
pubmed:
2
8
2021
medline:
2
8
2021
entrez:
1
8
2021
Statut:
ppublish
Résumé
The translocation t(15:19) produces the oncogenic BRD4-NUT fusion which is pathognomonic for NUT carcinoma (NC), which is a rare, but extremely aggressive solid tumor. Comprehensive genomic profiling (CGP) by hybrid-capture based next generation sequencing of 186+ genes of a cohort of advanced cancer cases with a variety of initial diagnoses harboring BRD4-NUT may shed further insight into the biology of these tumors and possible options for targeted treatment. Thirty-one solid tumor cases harboring a BRD4-NUT translocation are described, with only 16% initially diagnosed as NC and the remainder carrying other diagnoses, most commonly NSCLCNOS (22%) and lung squamous cell carcinoma (NSCLC-SCC) (16%). The cohort was all microsatellite stable and harbored a low Tumor Mutational Burden (TMB, mean 1.7 mut/mb, range 0-4). In two index cases, patients treated with immune checkpoint inhibitors (ICPI) had unexpected partial or better responses of varying duration. Notably, four cases - including the two index cases - were negative for PD-L1 expression. Neo-antigen prediction for BRD4-NUT and then affinity modeling of the peptide-MHC (pMHC) complex for an assessable index case predicted very high affinity binding, both on a ranked (99.9%) and absolute (33 nM) basis. CGP identifies BRD4-NUT fusions in advanced solid tumors which carry a broad range of initial diagnoses and which should be re-diagnosed as NC per guidelines. A hypothesized mechanism underlying responses to ICPI in the low TMB, PD-L1 negative index cases is the predicted high affinity of the BRD4-NUT fusion peptide to MHC complexes. Further study of pMHC affinity and response to immune checkpoint inhibitors in patients with NC harboring BRD4-NUT is needed to validate this therapeutic hypothesis.
Sections du résumé
BACKGROUND
BACKGROUND
The translocation t(15:19) produces the oncogenic BRD4-NUT fusion which is pathognomonic for NUT carcinoma (NC), which is a rare, but extremely aggressive solid tumor. Comprehensive genomic profiling (CGP) by hybrid-capture based next generation sequencing of 186+ genes of a cohort of advanced cancer cases with a variety of initial diagnoses harboring BRD4-NUT may shed further insight into the biology of these tumors and possible options for targeted treatment.
CASE PRESENTATION
METHODS
Thirty-one solid tumor cases harboring a BRD4-NUT translocation are described, with only 16% initially diagnosed as NC and the remainder carrying other diagnoses, most commonly NSCLCNOS (22%) and lung squamous cell carcinoma (NSCLC-SCC) (16%). The cohort was all microsatellite stable and harbored a low Tumor Mutational Burden (TMB, mean 1.7 mut/mb, range 0-4). In two index cases, patients treated with immune checkpoint inhibitors (ICPI) had unexpected partial or better responses of varying duration. Notably, four cases - including the two index cases - were negative for PD-L1 expression. Neo-antigen prediction for BRD4-NUT and then affinity modeling of the peptide-MHC (pMHC) complex for an assessable index case predicted very high affinity binding, both on a ranked (99.9%) and absolute (33 nM) basis.
CONCLUSIONS
CONCLUSIONS
CGP identifies BRD4-NUT fusions in advanced solid tumors which carry a broad range of initial diagnoses and which should be re-diagnosed as NC per guidelines. A hypothesized mechanism underlying responses to ICPI in the low TMB, PD-L1 negative index cases is the predicted high affinity of the BRD4-NUT fusion peptide to MHC complexes. Further study of pMHC affinity and response to immune checkpoint inhibitors in patients with NC harboring BRD4-NUT is needed to validate this therapeutic hypothesis.
Identifiants
pubmed: 34333275
pii: S1936-5233(21)00176-5
doi: 10.1016/j.tranon.2021.101184
pmc: PMC8340305
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101184Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Nat Med. 2019 May;25(5):767-775
pubmed: 31011208
Cancer Discov. 2014 Aug;4(8):928-41
pubmed: 24875858
PLoS One. 2007 Aug 29;2(8):e796
pubmed: 17726526
Clin Ther. 2015 Apr 1;37(4):764-82
pubmed: 25823918
Genome Med. 2017 Feb 24;9(1):16
pubmed: 28231819
Orphanet J Rare Dis. 2020 Jul 10;15(1):183
pubmed: 32650830
Cancer. 2016 Dec 1;122(23):3632-3640
pubmed: 27509377
Clin Cancer Res. 2012 Oct 15;18(20):5773-9
pubmed: 22896655
Appl Immunohistochem Mol Morphol. 2020 Aug;28(7):495-500
pubmed: 31180909
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Cancer Discov. 2016 May;6(5):492-500
pubmed: 26976114
J Clin Oncol. 2018 Oct 20;36(30):3007-3014
pubmed: 29733771
Cell Mol Life Sci. 2005 May;62(9):1025-37
pubmed: 15868101
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Head Neck Pathol. 2013 Mar;7(1):11-6
pubmed: 23463074
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Blood. 2016 Jun 16;127(24):3004-14
pubmed: 26966091
Case Rep Oncol. 2017 Nov 6;10(3):987-991
pubmed: 29279703
JNCI Cancer Spectr. 2019 Nov 06;4(2):pkz093
pubmed: 32328561
Am J Surg Pathol. 2009 Jul;33(7):984-91
pubmed: 19363441
BMC Cancer. 2018 Feb 27;18(1):225
pubmed: 29486723
Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821
pubmed: 29356890
Bioinformatics. 2014 Dec 1;30(23):3310-6
pubmed: 25143287
J Clin Oncol. 2004 Oct 15;22(20):4135-9
pubmed: 15483023